153 related articles for article (PubMed ID: 34858329)
1. Delayed Initial Radioiodine Adjuvant Therapy Does Affect Biochemical Response in Intermediate- to High-Risk Differentiated Thyroid Cancer.
Yu F; Li X; Ji Y; Tan J; Zhang G; Wang P; He Y; Wang R
Front Endocrinol (Lausanne); 2021; 12():743310. PubMed ID: 34858329
[TBL] [Abstract][Full Text] [Related]
2. Delayed initial radioiodine therapy related to incomplete response in low- to intermediate-risk differentiated thyroid cancer.
Li H; Zhang YQ; Wang C; Zhang X; Li X; Lin YS
Clin Endocrinol (Oxf); 2018 Apr; 88(4):601-606. PubMed ID: 29338092
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer.
Jeong JH; Kong EJ; Jeong SY; Lee SW; Cho IH; Ah Chun K; Lee J; Ahn BC
Nucl Med Commun; 2017 Mar; 38(3):228-233. PubMed ID: 27984538
[TBL] [Abstract][Full Text] [Related]
4. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
[TBL] [Abstract][Full Text] [Related]
5. Higher adjuvant radioactive iodine therapy dosage helps intermediate-risk papillary thyroid carcinoma patients achieve better therapeutic effect.
Li X; Zheng H; Ma C; Ji Y; Wang X; Sun D; Meng Z; Zheng W
Front Endocrinol (Lausanne); 2023; 14():1307325. PubMed ID: 38298190
[TBL] [Abstract][Full Text] [Related]
6. Development of a predictive nomogram for intermediate-risk differentiated thyroid cancer patients after fixed 3.7GBq (100mCi) radioiodine remnant ablation.
Lu L; Li Q; Ge Z; Lu Y; Lin C; Lv J; Huang J; Mu X; Fu W
Front Endocrinol (Lausanne); 2024; 15():1361683. PubMed ID: 38872967
[TBL] [Abstract][Full Text] [Related]
7. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
Liu YQ; Li H; Liu JR; Lin YS
Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
[No Abstract] [Full Text] [Related]
8. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
[TBL] [Abstract][Full Text] [Related]
9. Delay of initial radioactive iodine therapy beyond 3 months has no effect on clinical responses and overall survival in patients with thyroid carcinoma: A cohort study and a meta-analysis.
Cheng F; Xiao J; Huang F; Shao C; Ding S; Yun C; Jia H
Cancer Med; 2022 Jun; 11(12):2386-2396. PubMed ID: 35179295
[TBL] [Abstract][Full Text] [Related]
10. Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma.
Jeon MJ; Kim WG; Park WR; Han JM; Kim TY; Song DE; Chung KW; Ryu JS; Hong SJ; Shong YK; Kim WB
Eur J Endocrinol; 2014 Jan; 170(1):23-30. PubMed ID: 24088549
[TBL] [Abstract][Full Text] [Related]
11. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
Scheffel RS; Zanella AB; Dora JM; Maia AL
Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
[TBL] [Abstract][Full Text] [Related]
12. Is radioiodine ablation with 1.1 GBq (30 mCi)
Ilera V; Califano I; Cavallo A; Faure E; Vázquez A; Pitoia F;
Endocrine; 2023 Jun; 80(3):606-611. PubMed ID: 36988853
[TBL] [Abstract][Full Text] [Related]
13. Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer.
Tsirona S; Vlassopoulou V; Tzanela M; Rondogianni P; Ioannidis G; Vassilopoulos C; Botoula E; Trivizas P; Datseris I; Tsagarakis S
Clin Endocrinol (Oxf); 2014 Mar; 80(3):459-63. PubMed ID: 23895145
[TBL] [Abstract][Full Text] [Related]
14. Relapse-free survival after adjuvant radioactive iodine therapy in patients with differentiated thyroid carcinoma with a microscopically positive tumor margin.
Watanabe K; Igarashi T; Uchiyama M; Ojiri H
Ann Nucl Med; 2020 Dec; 34(12):920-925. PubMed ID: 32940889
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma.
Yang Z; Flores J; Katz S; Nathan CA; Mehta V
Thyroid; 2017 Jul; 27(7):944-952. PubMed ID: 28446057
[TBL] [Abstract][Full Text] [Related]
16. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
Iizuka Y; Katagiri T; Ogura K; Mizowaki T
Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
[TBL] [Abstract][Full Text] [Related]
17. Intermediate-risk differentiated thyroid carcinoma patients who were surgically ablated do not need adjuvant radioiodine therapy: long-term outcome study.
Ballal S; Soundararajan R; Garg A; Chopra S; Bal C
Clin Endocrinol (Oxf); 2016 Mar; 84(3):408-16. PubMed ID: 25823589
[TBL] [Abstract][Full Text] [Related]
18. Impact factors of benefiting from initial 131 I ablation in patients with intermediate-risk differentiated thyroid carcinoma: a study based on a re-evaluation of therapeutic response.
Ren L; Hu Y; Hu Y; Xiao D; Sun J; Zhu B; Zhang C
Nucl Med Commun; 2024 Mar; 45(3):188-195. PubMed ID: 38165164
[TBL] [Abstract][Full Text] [Related]
19. In Patients With Low- to Intermediate-Risk Thyroid Cancer, a Preablative Thyrotropin Level of 30 μIU/mL Is Not Adequate to Achieve Better Response to 131I Therapy.
Zhao T; Liang J; Guo Z; Li T; Lin Y
Clin Nucl Med; 2016 Jun; 41(6):454-8. PubMed ID: 26914559
[TBL] [Abstract][Full Text] [Related]
20. Unexplained Hyperthyroglobulinemia in Differentiated Thyroid Cancer Patients as an Indication for Radioiodine Adjuvant Therapy: A Prospective Multicenter Study.
Cheng L; Sa R; Luo Q; Fu H; Jin Y; Tang L; Yang Y; Yu C; Chen L
J Nucl Med; 2021 Jan; 62(1):62-68. PubMed ID: 32358095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]